GOLGA8K inhibitors represent a chemical class designed to specifically target and hinder the activity of the GOLGA8K protein. GOLGA8K, a member of the golgin family of proteins, plays a crucial role in the maintenance of the Golgi apparatus structure and function, as well as in vesicle tethering and trafficking. Inhibitors targeting GOLGA8K must, therefore, interact with the protein's unique features or its associated pathways to achieve functional suppression. These compounds are characterized by their ability to disrupt the normal functioning of GOLGA8K through direct binding or by interfering with its interaction partners or upstream regulators that are essential for its activity. The specificity of these inhibitors is critical, as it ensures minimal off-target effects, preserving the integrity of other golgins and associated cellular processes. The chemical structures within this class are diverse, often reflecting the complexity of the interactions they are designed to disrupt. They may act at the protein-protein interaction interfaces, allosteric sites or may interfere with post-translational modifications that are necessary for GOLGA8K's function.
The mechanism of action for GOLGA8K inhibitors encompasses a variety of biochemical interactions. Some members of this class inhibit the function of GOLGA8K by preventing its localization to the Golgi membrane, which is essential for its role in membrane trafficking. Others might inhibit the protein indirectly by targeting regulatory kinases or phosphatases that modulate GOLGA8K's activity through phosphorylation or dephosphorylation. The downstream effects of these inhibitors include altered Golgi apparatus dynamics, disruptions in vesicle formation, and trafficking anomalies, leading to a decrease in the efficacy of intracellular transport processes that GOLGA8K facilitates. This can result in a cascade of cellular dysfunctions, highlighting the pivotal role of GOLGA8K in cell homeostasis. As research progresses, the development of these inhibitors becomes more refined, with a focus on increasing specificity and reducing effects that may arise from perturbing the critical functions of the Golgi apparatus.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $68.00 $312.00 | 2 | |
Alsterpaullone is a known inhibitor of cyclin-dependent kinases (CDKs), which can indirectly affect the function of GOLGA8K by altering the cell cycle regulation and potentially affecting the Golgi apparatus dynamics of which GOLGA8K is a part. | ||||||
Brefeldin A | 20350-15-6 | sc-200861C sc-200861 sc-200861A sc-200861B | 1 mg 5 mg 25 mg 100 mg | $31.00 $53.00 $124.00 $374.00 | 25 | |
Brefeldin A disrupts the structure and function of the Golgi apparatus by inhibiting the ADP-ribosylation factor, which could lead to a functional inhibition of GOLGA8K by compromising the integrity and maintenance of the Golgi where it resides. | ||||||
Monensin A | 17090-79-8 | sc-362032 sc-362032A | 5 mg 25 mg | $155.00 $525.00 | ||
Monensin acts as an ionophore that alters the Golgi apparatus pH and cation homeostasis, indirectly affecting GOLGA8K by disturbing its Golgi localization and function. | ||||||
Nocodazole | 31430-18-9 | sc-3518B sc-3518 sc-3518C sc-3518A | 5 mg 10 mg 25 mg 50 mg | $59.00 $85.00 $143.00 $247.00 | 38 | |
Nocodazole disrupts microtubule polymerization, which could lead to mislocalization of GOLGA8K due to the dependence of Golgi positioning and function on the microtubule network. | ||||||
Dynamin Inhibitor I, Dynasore | 304448-55-3 | sc-202592 | 10 mg | $89.00 | 44 | |
Dynasore inhibits dynamin, a GTPase involved in membrane fission, which could indirectly inhibit GOLGA8K by affecting vesicle trafficking processes that are essential for Golgi apparatus function. | ||||||
Golgicide A | 1005036-73-6 | sc-215103 sc-215103A | 5 mg 25 mg | $191.00 $683.00 | 11 | |
Golgicide A is a specific inhibitor of the Golgi BFA resistance factor 1, which could disrupt the normal function of the Golgi apparatus and therefore indirectly inhibit GOLGA8K. | ||||||
Tunicamycin | 11089-65-9 | sc-3506A sc-3506 | 5 mg 10 mg | $172.00 $305.00 | 66 | |
Tunicamycin inhibits N-linked glycosylation, which could lead to GOLGA8K dysfunction by preventing proper folding and trafficking of glycoproteins within the Golgi apparatus. | ||||||
Swainsonine | 72741-87-8 | sc-201362 sc-201362C sc-201362A sc-201362D sc-201362B | 1 mg 2 mg 5 mg 10 mg 25 mg | $138.00 $251.00 $631.00 $815.00 $1832.00 | 6 | |
Swainsonine inhibits mannosidase II, which could lead to a buildup of misprocessed glycoproteins in the Golgi, potentially disrupting GOLGA8K's function within the organelle. | ||||||
Colchicine | 64-86-8 | sc-203005 sc-203005A sc-203005B sc-203005C sc-203005D sc-203005E | 1 g 5 g 50 g 100 g 500 g 1 kg | $100.00 $321.00 $2289.00 $4484.00 $18207.00 $34749.00 | 3 | |
Colchicine binds to tubulin and prevents its polymerization, which could indirectly inhibit GOLGA8K by disrupting the microtubule network required for Golgi stability and function. | ||||||
Cytochalasin D | 22144-77-0 | sc-201442 sc-201442A | 1 mg 5 mg | $165.00 $486.00 | 64 | |
Cytochalasin D disrupts actin filament organization, which can indirectly inhibit GOLGA8K by affecting the structural integrity of the Golgi apparatus and related trafficking processes. | ||||||